Julio César Casasola Vargas
Research Subjects
Julio César Casasola Vargas has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Wilson Bautista-Molano
W. Bautista-Molano, MD, PhD, University Hospital Fundación Santa Fe de Bogotá, School of Medicine, Universidad El Bosque, Bogotá, Colombia
3 shared publications - Daniel Gerardo Fernández Ávila
Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia
2 shared publications - Daniel Palleiro
Instituto Nacional de Reumatología, Montevideo, Uruguay
2 shared publications - Diego Vila
Hospital Virgen del Carmen, Buenos Aires, Argentina
2 shared publications - Fernando Sommerfleck
F. Sommerfleck, MD, Sanatorio Julio Méndez, Buenos Aires, Argentina
2 shared publications - Ingris Peláez-Ballestas
Rheumatology Unit, Hospital General de Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico
2 shared publications
Latest Publications
- 15 September 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (12) , 7383-7390
Regional patterns of advanced therapy use and unmet disease control in axial spondyloarthritis across Latin America: a report from the ESPALDA-PANLAR registry
- 15 September 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (12) , 7383-7390
Regional patterns of advanced therapy use and unmet disease control in axial spondyloarthritis across Latin America: a report from the ESPALDA-PANLAR registry
- 16 September 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (10) , 1-9
Profile of patients with axial spondyloarthritis in Latin America: first report from the ESPALDA-PANLAR registry
Despite increasing recognition of axial spondyloarthritis (axSpA) in Latin America, regional data remain scarce. This study aims to describe the clinical, laboratory, and imaging features of axSpA in Latin America using data from the ESPALDA-PANLAR registry. A cross-sectional analysis was conducted using baseline data from the ESPALDA registry, which includes patients with axSpA across seven Latin American countries. Demographic, clinical, laboratory, and imaging data were collected. Patients were stratified by sex, HLA-B27 status, and radiographic classification. Multivariable logistic regression was performed to identify independent associations. A total of 220 patients were included (56% male), with a mean age of 46 years and median diagnostic delay of 93 months (IQR: 13–122). HLA-B27 was positive in 60% of patients, and 62% met radiographic axSpA classification criteria. In multivariable analysis, radiographic axSpA was independently associated with male sex (OR 4.22; 95% CI 1.53–11.59), SI joint erosions on MRI (OR 3.98; 95% CI 1.45–10.90), and longer diagnostic delay (OR 1.01 per month; 95% CI 1.00–1.01). HLA-B27 positivity was associated with bone marrow edema on MRI (OR 2.81; 95% CI 1.50–5.26) and inversely with psoriasis (OR 0.14; 95% CI 0.06–0.33). This first report from the ESPALDA registry highlights distinctive features of axSpA in Latin America, including lower HLA-B27 prevalence and remarkably diagnostic delay. These findings underscore the need for earlier recognition and regionally adapted strategies for diagnosis and management.
- 16 September 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (10) , 1-9
Profile of patients with axial spondyloarthritis in Latin America: first report from the ESPALDA-PANLAR registry
Despite increasing recognition of axial spondyloarthritis (axSpA) in Latin America, regional data remain scarce. This study aims to describe the clinical, laboratory, and imaging features of axSpA in Latin America using data from the ESPALDA-PANLAR registry. A cross-sectional analysis was conducted using baseline data from the ESPALDA registry, which includes patients with axSpA across seven Latin American countries. Demographic, clinical, laboratory, and imaging data were collected. Patients were stratified by sex, HLA-B27 status, and radiographic classification. Multivariable logistic regression was performed to identify independent associations. A total of 220 patients were included (56% male), with a mean age of 46 years and median diagnostic delay of 93 months (IQR: 13–122). HLA-B27 was positive in 60% of patients, and 62% met radiographic axSpA classification criteria. In multivariable analysis, radiographic axSpA was independently associated with male sex (OR 4.22; 95% CI 1.53–11.59), SI joint erosions on MRI (OR 3.98; 95% CI 1.45–10.90), and longer diagnostic delay (OR 1.01 per month; 95% CI 1.00–1.01). HLA-B27 positivity was associated with bone marrow edema on MRI (OR 2.81; 95% CI 1.50–5.26) and inversely with psoriasis (OR 0.14; 95% CI 0.06–0.33). This first report from the ESPALDA registry highlights distinctive features of axSpA in Latin America, including lower HLA-B27 prevalence and remarkably diagnostic delay. These findings underscore the need for earlier recognition and regionally adapted strategies for diagnosis and management.
- 15 October 2022
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 50 (1) , 119-130
Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
Objective: We aimed to compile evidence for the efficacy and safety of therapeutic options for the peripheral arthritis domain of psoriatic arthritis (PsA) for the revised 2021 Group in Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations.Methods: A working group consisting of clinicians and patient research partners was convened. We reviewed the evidence from new randomized controlled trials (RCTs) for PsA treatment from February 19, 2013, to August 28, 2020. We used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE)-informed approach to derive evidence for the classes of therapeutic options for 3 patient groups: (1) naïve to treatment, (2) inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), and (3) inadequate response to biologic DMARDs (bDMARDs). Recommendations were derived through consensus meetings.Results: The evidence review included 69 RCTs. We derived GRADE evidence for each class of therapeutic options and achieved consensus for the recommendations. For patients naïve to treatment, the working group strongly recommends csDMARDs (methotrexate, sulfasalazine, leflunomide) and phosphodiesterase 4 inhibitors, and emphasizes regular assessment and early escalation to achieve treatment target. bDMARDs (tumor necrosis factor inhibitors [TNFi], interleukin 17 inhibitors [IL-17i], IL-12/23i, IL-23i) and Janus kinase inhibitors (JAKi) are also strongly recommended. For patients with inadequate response to csDMARDs, we strongly recommend TNFi, IL-17i, IL-12/23i, IL-23i, and JAKi. For those who had prior experience with bDMARDs, we strongly recommend a second TNFi, IL-17i, IL-23i, and JAKi. The evidence supporting nonpharmacological interventions was very low. An expert panel conditionally recommends adequate physical activity, smoking cessation, and diet to control weight gain.Conclusion: Evidence supporting optimal therapy for the peripheral arthritis domain of PsA was compiled for the revised 2021 GRAPPA treatment recommendations.
- 15 October 2022
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 50 (1) , 119-130
Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
Objective: We aimed to compile evidence for the efficacy and safety of therapeutic options for the peripheral arthritis domain of psoriatic arthritis (PsA) for the revised 2021 Group in Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations.Methods: A working group consisting of clinicians and patient research partners was convened. We reviewed the evidence from new randomized controlled trials (RCTs) for PsA treatment from February 19, 2013, to August 28, 2020. We used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE)-informed approach to derive evidence for the classes of therapeutic options for 3 patient groups: (1) naïve to treatment, (2) inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), and (3) inadequate response to biologic DMARDs (bDMARDs). Recommendations were derived through consensus meetings.Results: The evidence review included 69 RCTs. We derived GRADE evidence for each class of therapeutic options and achieved consensus for the recommendations. For patients naïve to treatment, the working group strongly recommends csDMARDs (methotrexate, sulfasalazine, leflunomide) and phosphodiesterase 4 inhibitors, and emphasizes regular assessment and early escalation to achieve treatment target. bDMARDs (tumor necrosis factor inhibitors [TNFi], interleukin 17 inhibitors [IL-17i], IL-12/23i, IL-23i) and Janus kinase inhibitors (JAKi) are also strongly recommended. For patients with inadequate response to csDMARDs, we strongly recommend TNFi, IL-17i, IL-12/23i, IL-23i, and JAKi. For those who had prior experience with bDMARDs, we strongly recommend a second TNFi, IL-17i, IL-23i, and JAKi. The evidence supporting nonpharmacological interventions was very low. An expert panel conditionally recommends adequate physical activity, smoking cessation, and diet to control weight gain.Conclusion: Evidence supporting optimal therapy for the peripheral arthritis domain of PsA was compiled for the revised 2021 GRAPPA treatment recommendations.
- 19 June 2021
- Published by Springer Nature in Rheumatology International
- Vol. 42 (11) , 2049-2059
Qualitative validation of audiovisual educational material for use on rheumatoid arthritis patients
Medication compliance is critical to achieve therapeutic efficacy in patients with rheumatoid arthritis; however, among other factors, low patient-health literacy plays a negative role. Therefore, the development and validation of audiovisual educational material with the participation of health specialists and patients could lead to an improved level of compliance with treatment, while favoring its acceptance. To design and validate audiovisual educational material generated by a multidisciplinary and participative group of patients and health specialists. This study was carried out using a sequential methodology, including qualitative and quantitative techniques: (1) a non-participative observational study with patients and a non-systematic literature search were performed to identify conceptual topics. (2) Pilot videos were qualitatively assessed by patients and health specialists (focus groups and expert committees). (3) Improved versions of seven videos were quantitatively evaluated by patients and specialists following qualitative criteria of attraction, understanding, involvement, acceptance and induction of action. 74 patients with RA, 10 rheumatologists, 4 pharmacists and 2 medical anthropologists participated in the different phases of validation. A total of seven videos lasting 3 min each were generated, incorporating the most relevant suggestions by patients and healthcare professionals. The final version of the videos led to a mean compliance of 96.04 ± 5.2%, according to a representative group of patients and a mean 89.6 ± 9.4%, according to health professionals. With the participation of both patients and health specialists, seven audiovisual educational video recordings were developed and validated, reaching high levels of compliance in accordance with international criteria.
- 19 June 2021
- Published by Springer Nature in Rheumatology International
- Vol. 42 (11) , 2049-2059
Qualitative validation of audiovisual educational material for use on rheumatoid arthritis patients
Medication compliance is critical to achieve therapeutic efficacy in patients with rheumatoid arthritis; however, among other factors, low patient-health literacy plays a negative role. Therefore, the development and validation of audiovisual educational material with the participation of health specialists and patients could lead to an improved level of compliance with treatment, while favoring its acceptance. To design and validate audiovisual educational material generated by a multidisciplinary and participative group of patients and health specialists. This study was carried out using a sequential methodology, including qualitative and quantitative techniques: (1) a non-participative observational study with patients and a non-systematic literature search were performed to identify conceptual topics. (2) Pilot videos were qualitatively assessed by patients and health specialists (focus groups and expert committees). (3) Improved versions of seven videos were quantitatively evaluated by patients and specialists following qualitative criteria of attraction, understanding, involvement, acceptance and induction of action. 74 patients with RA, 10 rheumatologists, 4 pharmacists and 2 medical anthropologists participated in the different phases of validation. A total of seven videos lasting 3 min each were generated, incorporating the most relevant suggestions by patients and healthcare professionals. The final version of the videos led to a mean compliance of 96.04 ± 5.2%, according to a representative group of patients and a mean 89.6 ± 9.4%, according to health professionals. With the participation of both patients and health specialists, seven audiovisual educational video recordings were developed and validated, reaching high levels of compliance in accordance with international criteria.
- Open Access
- 1 January 2011
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 86, 26-30
Prevalence of Back Pain in the Community. A COPCORD-Based Study in the Mexican Population
Objective. Back pain (BP) is frequent in the community; its prevalence in México is 6%. Our objective was to determine the prevalence of BP in Mexican communities and determine its most important characteristics. Methods. A cross-sectional study of individuals aged > 18 years was conducted in Mexico City and in urban communities in the state of Nuevo León. Sampling in Mexico City was based on community census and in Nuevo León, on stratified, balanced, and random sampling. Procedures included a door-to-door survey, using the Community Oriented Program for the Control of Rheumatic Diseases, to identify individuals with BP > 1 on a visual analog scale in the last 7 days. General practitioners/rheumatology fellows confirmed and characterized BP symptoms. Results. In all, 8159 individuals (mean age 43.7 yrs, two-thirds female) were surveyed and 1219 had BP. The prevalence of nontraumatic BP in the last 7 days was 8.0% (95% CI 7.5–8.7). The mean age of these individuals was 42.7 years, and 61.9% were female. Thirty-seven percent had inflammatory BP [prevalence of 3.0% (95% CI 2.7–3.4)]. Compared with the state of Nuevo Léon, the characteristics and consequences of BP in Mexico City were more severe. In logistic regression analysis, living in Mexico City, having a paid job, any kind of musculoskeletal pain, high pain intensity, and obesity among other variables were associated with BP. Conclusion. The prevalence of nontraumatic BP in the last 7 days in urban communities in México is 8.0%. However, clinical features and consequences differed among the communities studied, suggesting a role for local factors in BP.
- 1 January 2011
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 86, 26-30
Open AccessPrevalence of Back Pain in the Community. A COPCORD-Based Study in the Mexican Population
Objective. Back pain (BP) is frequent in the community; its prevalence in México is 6%. Our objective was to determine the prevalence of BP in Mexican communities and determine its most important characteristics. Methods. A cross-sectional study of individuals aged > 18 years was conducted in Mexico City and in urban communities in the state of Nuevo León. Sampling in Mexico City was based on community census and in Nuevo León, on stratified, balanced, and random sampling. Procedures included a door-to-door survey, using the Community Oriented Program for the Control of Rheumatic Diseases, to identify individuals with BP > 1 on a visual analog scale in the last 7 days. General practitioners/rheumatology fellows confirmed and characterized BP symptoms. Results. In all, 8159 individuals (mean age 43.7 yrs, two-thirds female) were surveyed and 1219 had BP. The prevalence of nontraumatic BP in the last 7 days was 8.0% (95% CI 7.5–8.7). The mean age of these individuals was 42.7 years, and 61.9% were female. Thirty-seven percent had inflammatory BP [prevalence of 3.0% (95% CI 2.7–3.4)]. Compared with the state of Nuevo Léon, the characteristics and consequences of BP in Mexico City were more severe. In logistic regression analysis, living in Mexico City, having a paid job, any kind of musculoskeletal pain, high pain intensity, and obesity among other variables were associated with BP. Conclusion. The prevalence of nontraumatic BP in the last 7 days in urban communities in México is 8.0%. However, clinical features and consequences differed among the communities studied, suggesting a role for local factors in BP.